Pharmafile Logo

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Video: Syndicated patient record data

Track the global market in real time

Video: Patient level prescribing decisions

Quantitative Director Duncan Munro explores the benefits of using patient level prescribing decisions.There is no “one size fits all” approach to conducting demand assessments. The best studies utilise a methodology...

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

Pharmaceutical Market Research Conference 2016

Research Partnership exhibited and presented a paper at the Pharmaceutical Market Research Conference last week in Parsippany, NJ.Representing Research Partnership were US President Harriet Kozak and Director Phil Rosenberg.Harriet presented the paper...

Nicole Bender Moreira promoted to Associate Director, Singapore office

Research Partnership is delighted to announce the promotion of Nicole Bender Moreira to Associate Director in recognition of the contribution she has made to the growing success of our Singapore...

New appointments announced across Research Partnership’s global offices

We are delighted to welcome Marianne Jaeger as Associate Director to our London headquarters

What to Consider When Conducting Patient Research in Saudi Arabia

The need to understand the patient as a key stakeholder is now recognized by pharma across the globe.

Research Partnership hires Graphic Designer to create storytelling deliverables

Research Partnership has extended its healthcare research and consulting offering to include storytelling deliverables with the hire of multi-media graphic designer Amanda Brent at the company’s London headquarters. Working with...

Research Partnership is UK’s fastest growing healthcare market research specialist

The latest league tables for the UK market research industry have just been released and reveal Research Partnership to be the fastest growing healthcare market research specialist for 2014.With turnover...

Emerging Markets: Your Essential Guide

Using our combined knowledge and years of experience of working in these territories, our experts have produced an essential guide to help address some of the core challenges for conducting market...